Drug Profile
Research programme: GPCR peptide ligands - Compugen
Alternative Names: CGEN-25009; CGEN-25010; CGEN-25011; CGEN-857Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Compugen
- Developer Compugen; University of Pittsburgh
- Class Peptides
- Mechanism of Action FPR2 protein stimulants; G protein-coupled receptor agonists; RXFP1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cardiovascular disorders; Pulmonary fibrosis
Highest Development Phases
- No development reported Cardiovascular disorders; Inflammation; Myocardial infarction; Pulmonary fibrosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Israel (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Israel (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Myocardial-infarction in Israel (Parenteral)